

Appl. No. 10/606,632
Reply to Office Action of January 25, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (Canceled).

6. (Currently Amended) A pharmaceutical composition comprising a diuretic and an insulin sensitizer in ratio of amount by weight of 1:200 to 200:1, wherein said insulin sensitizer is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof; and A pharmaceutical composition according to Claim 4, wherein said diuretic is amiloride.

Claims 7-21 (Canceled).


Appl. No. 10/606,632
Reply to Office Action of January 25, 2006

22. (New) A pharmaceutical composition comprising a diuretic and an insulin sensitizer in a ratio of amounts by weight of 1:200 to 200:1, wherein


said diuretic is amiloride; and

said insulin sensitizer comprises one or more compounds selected from the group consisting of troglitazone, pioglitazone, rosiglitazone, JTT-501, MCC-555, GI-262570, YM-440, KRP-297, T-174, NC-2100, BMS-298585, AZ-242 and NN-622 represented by the formula below


Appl. No. 10/606,632
Reply to Office Action of January 25, 2006




Pioglitazone




Rosiglitazone




JTT-501




MCC-555



GI-262570




YM-440




KRP-297


Appl. No. 10/606,632
Reply to Office Action of January 25, 2006




T-174




NC-2100



BMS-298585



AZ-242



NN-622

Appl. No. 10/606,632
Reply to Office Action of January 25, 2006

5-[4-(6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof.

23. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is troglitazone.

24. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is pioglitazone.

25. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is rosiglitazone.

26. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is JTT-501.

27. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is MCC-555.

28. (New) The pharmaceutical composition of claim 22, wherein said insulin sensitizer is GI-262570.

Appl. No. 10/606,632
Reply to Office Action of January 25, 2006

29. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is YM-440.

30. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is KRP-297.

31. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is T-174.

32. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is NC-2100.

33. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is BMS-298585.

34. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is AZ-242.

35. (New) The pharmaceutical composition of claim 22,
wherein said insulin sensitizer is NN-622.